To identify potential SL genes for TP53 we hypothesize that TP53 SL partners (oncogenes) are hyper-activated in TP53-mutated cancers compared to both TP53-wildtype cancers and normal tissue, as TP53-mutated cancer cells have to rely more heavily on TP53's SL partners for survival than TP53-wildtype cancer cells or normal cells. This evidence concerns the gene TP53 and cancer.